Rational treatment of acute rhinosinusitis in children

Acute rhinosinusitis is among the most common respiratory conditions in children, particularly during periods of active socialization and immunological immaturity. Despite its predominantly viral etiology, antibiotics are frequently prescribed inappropriately, emphasizing the need for safe and effective pathogenetic treatment strategies. Aim - to assess the clinical efficacy and tolerability of the complex homeopathic medicinal product Cinnabsin in the treatment of acute viral rhinosinusitis in children, compared to standard symptomatic therapy. Materials and methods. A total of 65 children aged 5-15 years with signs of acute upper respiratory tract infection were enrolled in this observational study. The treatment group (n=36) received Cinnabsin along with nasal saline irrigation, while the control group (n=29) was treated with nasal saline irrigation, decongestants, and mucoactive agents. Clinical symptoms were evaluated on days 3 and 7 using a 5-point Visual Analogue Scale (VAS), an objective symptom severity score, and odds ratios (OR) to quantify treatment effects. Treatment tolerability was assessed based on parental and physician ratings. Results. By day 3, the treatment group showed a more pronounced reduction in key nasal symptoms, particularly nasal obstruction and rhinorrhea. On day 7, significant improvement was observed in the treatment group (p<0.05), with ORs ranging from 2.38 to 5.86 in favour of the treatment group. Tolerability was rated as "Very good" in 94.4% of cases, and no adverse effects associated with Cinnabsin were reported. Conclusions. Cinnabsin demonstrated high clinical efficacy and excellent tolerability in the management of acute viral rhinosinusitis in children, particularly in alleviating nasal symptoms. These findings support its use as a rational pathogenetic therapy in pediatric clinical practice. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee for all participants. The informed consent was obtained from patients. The author declares no conflict of interest.